Elanco Animal Health (ELAN) Set to Announce Earnings on Tuesday

Elanco Animal Health (NYSE:ELAN) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 7th. Analysts expect Elanco Animal Health to post earnings of $0.12 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Monday, August 7th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.05 by $0.13. The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.04 billion. Elanco Animal Health had a positive return on equity of 6.93% and a negative net margin of 2.24%. The firm’s revenue for the quarter was down 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.36 EPS. On average, analysts expect Elanco Animal Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Elanco Animal Health Stock Performance

ELAN opened at $9.61 on Friday. The business has a fifty day simple moving average of $10.61 and a 200 day simple moving average of $10.37. The company has a market capitalization of $4.73 billion, a PE ratio of -48.05, a price-to-earnings-growth ratio of 5.79 and a beta of 1.02. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.84 and a quick ratio of 1.53. Elanco Animal Health has a 1 year low of $7.88 and a 1 year high of $14.69.

Analyst Ratings Changes

A number of equities analysts have recently commented on ELAN shares. Stifel Nicolaus lowered their price target on Elanco Animal Health from $13.00 to $12.00 and set a “hold” rating for the company in a report on Monday, October 30th. Piper Sandler lowered their price target on Elanco Animal Health from $13.00 to $11.00 in a report on Thursday, October 5th. Finally, The Goldman Sachs Group boosted their price target on Elanco Animal Health from $8.50 to $9.50 and gave the stock a “sell” rating in a report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $13.10.

Institutional Investors Weigh In On Elanco Animal Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Captrust Financial Advisors boosted its position in shares of Elanco Animal Health by 57.0% during the 1st quarter. Captrust Financial Advisors now owns 2,690 shares of the company’s stock valued at $70,000 after purchasing an additional 977 shares in the last quarter. Covestor Ltd boosted its holdings in Elanco Animal Health by 1,285.1% in the first quarter. Covestor Ltd now owns 2,978 shares of the company’s stock worth $78,000 after acquiring an additional 2,763 shares in the last quarter. Advisory Services Network LLC boosted its holdings in Elanco Animal Health by 104.1% in the first quarter. Advisory Services Network LLC now owns 5,204 shares of the company’s stock worth $49,000 after acquiring an additional 2,654 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in Elanco Animal Health in the fourth quarter worth approximately $70,000. Finally, Pearl River Capital LLC bought a new position in Elanco Animal Health in the first quarter worth approximately $205,000. Institutional investors own 95.29% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.